[{"AccountsPayableCurrent_0_Q2_USD":3658052.0,"ProfitLoss_1_Q2_USD":-8155222.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":998802.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":61934439.0,"PrepaidExpenseCurrent_0_Q2_USD":386809.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ProfitLoss_2_Q2_USD":-16010287.0,"PaymentsOfFinancingCosts_2_Q2_USD":1134697.0,"OperatingExpenses_1_Q2_USD":8954586.0,"NonoperatingIncomeExpense_2_Q2_USD":2426743.0,"NonoperatingIncomeExpense_1_Q2_USD":826352.0,"NetIncomeLoss_2_Q2_USD":-16010287.0,"NetIncomeLoss_1_Q2_USD":-8155222.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-15188223.0,"OperatingExpenses_2_Q2_USD":18350761.0,"ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1_Q2_USD":960879.0,"ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_Q2_USD":2230195.0,"ResearchAndDevelopmentExpense_1_Q2_USD":6720841.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":998802.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":998802.0,"StockIssuedDuringPeriodValueOther_2_Q2_USD":36688544.0,"StockIssuedDuringPeriodValueOther_1_Q2_USD":28169987.0,"StockIssuedDuringPeriodValueNewIssues_2_Q2_USD":24111198.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":6649796.0,"StockholdersEquity_0_Q2_USD":75810296.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q2_shares":500000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_Q2_pure":0.0064,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_Q2_pure":0.9626,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"ShareBasedCompensation_2_Q2_USD":2785470.0,"ShareBasedCompensation_1_Q2_USD":1846156.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-175687517.0,"ResearchAndDevelopmentExpense_2_Q2_USD":14646360.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":61798544.0,"LiabilitiesCurrent_0_Q2_USD":7763942.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":83574238.0,"LeaseAndRentalExpense_2_Q2_USD":60861.0,"CurrentIncomeTaxExpenseBenefit_2_Q2_USD":86269.0,"CurrentIncomeTaxExpenseBenefit_1_Q2_USD":26988.0,"CommonStockValue_0_Q2_USD":70032.0,"CommonStockSharesOutstanding_0_Q2_shares":70030620.0,"CommonStockSharesIssued_0_Q2_shares":70030620.0,"CommonStockSharesAuthorized_0_Q2_shares":100000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":46610321.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":75859339.0,"Assets_0_Q2_USD":83574238.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":11505199.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":1846156.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":2785470.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":251427781.0,"AccruedLiabilitiesCurrent_0_Q2_USD":3618779.0,"DeferredIncomeCurrent_0_Q2_USD":487111.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":68594867.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.12,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q2_USD":7091142.0,"LeaseAndRentalExpense_1_Q2_USD":29903.0,"InterestIncomeExpenseNet_2_Q2_USD":7657.0,"InterestIncomeExpenseNet_1_Q2_USD":9216.0,"IncreaseDecreaseInPrepaidExpense_2_Q2_USD":-57030.0,"IncreaseDecreaseInIncomeTaxesReceivable_2_Q2_USD":2478750.0,"IncreaseDecreaseInDeferredRevenue_2_Q2_USD":487111.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":302205.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-331002.0,"IncomeTaxesReceivable_0_Q2_USD":7328090.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-15924018.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-8128234.0,"GeneralAndAdministrativeExpense_2_Q2_USD":3704401.0,"GeneralAndAdministrativeExpense_1_Q2_USD":2233745.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":178071.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q2_USD":-154563.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.24,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":66421380.0,"Ticker":"AVXL","CIK":"1314052","name":"ANAVEX LIFE SCIENCES CORP.","OfficialName":"Anavex Life Sciences Corp. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"825317693.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20210513"}]